Sol-Gel将向PellePharm支付470万美元的预付款,以及高达600万美元的开发和NDA验收里程碑,以及高达6400万美元的商业里程碑和分成。
Patidegib被Sol-Gel指定为SGT-610,用于治疗Go...查看全文
$Sol-gel(SLGL)$ EFFECT - Notice of Effectiveness Filed: 2019-04-12 AccNo: 9999999995-19-000694 Size: 1 KB 网页链接
$Sol-gel(SLGL)$ F-3/A [Amend] - Registration statement by foreign private issuers Filed: 2019-04-10 AccNo: 0001178913-19-001102 Size: 530 KB 网页链接
$Sol-gel(SLGL)$ F-3 - Registration statement by foreign private issuers Filed: 2019-03-28 AccNo: 0001178913-19-000979 Size: 324 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-03-22 AccNo: 0001178913-19-000899 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Filed: 2019-03-21 AccNo: 0001178913-19-000896 Size: 6 MB 网页链接
$Sol-gel(SLGL)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2019-02-14 AccNo: 0001178913-19-000514 Size: 187 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-02-06 AccNo: 0001178913-19-000305 Size: 26 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-01-15 AccNo: 0001178913-19-000097 Size: 34 KB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2019-01-07 AccNo: 0001178913-19-000060 Size: 2 MB 网页链接
$Sol-gel(SLGL)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-12-26 AccNo: 0001178913-18-003207 Size: 36 KB 网页链接